Compare DNN & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DNN | VRDN |
|---|---|---|
| Founded | 1954 | 2006 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Medical Specialities |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.1B |
| IPO Year | 1998 | 2014 |
| Metric | DNN | VRDN |
|---|---|---|
| Price | $2.21 | $24.57 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 15 | 17 |
| Target Price | $4.73 | ★ $36.20 |
| AVG Volume (30 Days) | ★ 26.8M | 2.0M |
| Earning Date | 11-03-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $5,706,000.00 |
| Revenue This Year | $321.58 | N/A |
| Revenue Next Year | $38.26 | $878.45 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.10 | $13.18 |
| 52 Week High | $4.43 | $34.29 |
| Indicator | DNN | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 36.99 | 68.17 |
| Support Level | $2.10 | $21.40 |
| Resistance Level | $3.43 | $24.86 |
| Average True Range (ATR) | 0.12 | 1.00 |
| MACD | 0.03 | 0.57 |
| Stochastic Oscillator | 23.44 | 88.72 |
Denison Mines Corp is engaged in uranium mining-related activities, including the acquisition, exploration, development, and mining of uranium-bearing properties, as well as the processing, sale, and investment in uranium. The company's key properties include Wheeler River, Waterbury Lake, McClean Lake, Midwest, and others. It operates through two segments: the Mining segment and the Corporate and Other segment. The majority of the company's revenue is generated from the Mining segment, which includes activities related to exploration, evaluation, and development, mining, milling (including toll milling), and the sale of mineral concentrates.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.